Advancing Research Needed to Develop a Universal Influenza Vaccine (R21 Clinical Trial Not Allowed) | PA 18 858

Opportunity Information: Apply for PA 18 858

The funding opportunity titled "Advancing Research Needed to Develop a Universal Influenza Vaccine (R21 Clinical Trial Not Allowed)" (Funding Opportunity Number PA 18-858) is a National Institutes of Health (NIH) discretionary grant program led by the National Institute of Allergy and Infectious Diseases (NIAID). Its central goal is to move the field closer to a universal influenza vaccine, meaning a vaccine that can provide broad, durable protection across many influenza strains rather than needing frequent reformulation. The program is designed to support research that directly advances NIAID's universal flu vaccine mission by strengthening the scientific foundation needed to design next-generation influenza vaccines with wider and longer-lasting effectiveness.

The announcement highlights three major research priorities. First, it seeks studies that improve understanding of influenza virus transmission, the natural history of infection, and mechanisms of pathogenesis, essentially focusing on how influenza spreads, how disease develops over time in different hosts, and what biological processes drive severity. Second, it encourages work that characterizes influenza immunity and identifies correlates of immune protection, which includes defining what immune responses (such as particular antibody functions, T-cell responses, mucosal immunity, or innate immune signatures) actually predict protection from infection or severe disease. Third, it supports rational design approaches for universal influenza vaccines, which can involve using immunological insights and viral biology to guide antigen selection, epitope targeting, platform choices, and strategies meant to elicit broadly protective responses. Taken together, the FOA emphasizes research that clarifies the rules of influenza immunity and viral behavior so vaccine design can be more systematic and predictive rather than trial-and-error.

This opportunity uses the NIH R21 mechanism, which is typically meant for exploratory, developmental projects and is often a good fit for high-risk/high-reward ideas. The FOA explicitly notes that projects without extensive preliminary data, as well as projects that may rely on existing datasets or samples, can be especially appropriate for R21 support. In parallel, NIH points applicants to a companion R01 opportunity (referenced as PA-XX-xxx in the text) intended for applicants who already have strong preliminary data or who need a longer-term, more comprehensive funding structure. In practice, the R21 is positioned as a way to test bold concepts, generate proof-of-concept results, or open new directions that could later mature into larger R01-style programs.

A key restriction is embedded in the title: clinical trials are not allowed under this R21 announcement. That means the funded work should not include prospective assignment of human participants to interventions to evaluate health-related outcomes in a way NIH defines as a clinical trial. Applicants can still often conduct important non-trial human-focused research (for example, analysis of samples from prior studies, observational immunology studies depending on design, or laboratory and computational work), but the research plan must remain within the "clinical trial not allowed" boundary.

From an administrative and eligibility standpoint, this is a grant (Funding Instrument Type: Grant) in the health funding activity category and is associated with CFDA number 93.855. Eligibility is broad and includes many categories of U.S.-based organizations such as state, county, and local governments; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; special district governments; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; tribal organizations that are not federally recognized governments; nonprofits with and without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations other than small businesses; and small businesses. The FOA also explicitly calls out additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). This wide eligibility reflects an intent to draw on diverse institutional strengths, including international expertise that may be critical for understanding influenza evolution, transmission dynamics, and immune responses across different settings.

In terms of key dates and funding parameters provided in the source details, the opportunity was created on 2018-07-18, and the listed original closing date is 2021-09-07. The award ceiling provided is $200,000, indicating the maximum award amount expected under the announcement (often per year or per project period depending on NIH FOA specifics, but the provided dataset lists the ceiling as a single figure). The number of expected awards is not specified in the excerpted source data. Overall, the program is best understood as targeted seed funding for innovative, non-clinical-trial research that strengthens the evidence base and design logic needed to achieve a broadly protective, durable universal influenza vaccine.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Advancing Research Needed to Develop a Universal Influenza Vaccine (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
• This funding opportunity was created on 2018-07-18.
• Applicants must submit their applications by 2021-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $200,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PA 18 858

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: